Results 41 to 50 of about 1,770,471 (326)
Synthetic Lethality in Cancer Therapeutics: The Next Generation
Cancer Discovery, 2021 Synthetic lethality (SL) provides a conceptual framework for tackling targets that are not classically ‘druggable,’ including loss-of-function mutations in tumor suppressor genes required for carcinogenesis.
J. Setton +7 more
semanticscholar +1 more source
Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy [PDF]
, 2014 Phosphatase and tensin homolog (PTEN) loss is associated with genomic instability. APE1 is a key player in DNA base excision repair (BER) and an emerging drug target in cancer.
Allinson +49 more
core +2 more sources
Cancer Research, 2022 DNA repair pathway inhibitors are a new class of anti-cancer drugs that are advancing in clinical trials. Peposertib is an inhibitor of DNA-dependent protein kinase (DNA-PK), which is a key driver of non-homologous end-joining (NHEJ).
Jeffrey Patterson-Fortin +12 more
semanticscholar +1 more source
Synthetic Lethality Approaches in Acute Lymphoblastic Leukemia
Hemato, 2023 Acute lymphoblastic leukemia (ALL), a remarkable cancer that mainly affects children, has seen commendable advances in its treatment. However, the occurrence of relapses after initial treatments poses a major threat and is one of the leading causes of ...
Francisco Alejandro Lagunas-Rangel +1 more
doaj +1 more source
PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer
Cancer Research, 2021 This study demonstrates that PARP and ATR inhibitors are synthetic lethal with the loss of PBRM1, a PBAF-specific subunit, thus providing the rationale for assessing these inhibitors in patients with PBRM1-defective cancer.
R. Chabanon +27 more
semanticscholar +1 more source
Nature Nanotechnology, 2017 Nanoparticles loaded with paclitaxel and nintedanib induce synthetic lethality in endometrial cancer cells.
Rolfo, Christian, Giovannetti, Elisa
openaire +3 more sources
Cell Death Discovery, 2022 Many genes responsible for Malignant mesothelioma (MM) have been identified as tumor suppressor genes and it is difficult to target these genes directly at a molecular level.
Koya Suzuki +14 more
doaj +1 more source
Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy [PDF]
, 2014 BRCA1, a key factor in homologous recombination repair may also regulate base excision repair (BER). Targeting BRCA1-BER deficient cells by blockade of ATM and DNA-PKcs could be a promising strategy in breast cancer.
Abdel-Fatah, TMA +16 more
core +1 more source
Cancer Research, 2022 BRCA1-mediated homologous recombination is an important DNA repair mechanism that is the target of FDA-approved PARP inhibitors, yet details of BRCA1-mediated functions remain to be fully elucidated.
A. Kornepati +19 more
semanticscholar +1 more source
A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. [PDF]
, 2016 mTOR inhibition has emerged as a promising strategy for head and neck squamous cell carcinomas (HNSCC) treatment. However, most targeted therapies ultimately develop resistance due to the activation of adaptive survival signaling mechanisms limiting the ...
Amornphimoltham, Panomwat +10 more
core +1 more source